Press Releases

13.02.2018

• MOLOGEN to receive a EUR 3 million initial payment as well as a EUR 2 million equity investment • Milestone payments of above EUR 100 million and double digit royalties on net sales • Strong support for global development program of...

22.01.2018

Berlin, 22 January 2018 – The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presented data on its lead compound, the TLR9 agonist and immune surveillance reactivator lefitolimod, at the Annual...

       

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.